Lumos Pharma, Inc.
LUMO
$-0.06
Change (1 day)
$4.55
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Stock split history for Lumos Pharma, Inc. (LUMO)
Lumos Pharma, Inc. stock (symbol: LUMO) underwent a total of 1 stock splits.
The most recent stock split occured on Mar 19, 2020.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2020-03-19 | 1:9 | 1 |